Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Summary, in English

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

• Författare: Pia Burman; Britt Edén-Engström; Bertil Ekman; F Anders Karlsson; Erik Schwarcz; Jeanette Wahlberg
• Avdelning/ar: Translationell Muskel Forskning
• Publiceringsår: 2016
• Språk: Engelska
• Sidor: 17-24
• Publikation/Tidskrift/Serie: European Journal of Endocrinology
• Volym: 174
• Issue: 1
• Länkar: http://www.ncbi.nlm.nih.gov/pubmed/26582653?dopt=Abstract; http://dx.doi.org/10.1530/EJE-15-0807
• Dokumenttyp: Artikel i tidskrift
• Förlag: Society of the European Journal of Endocrinology
• Ämne: Endocrinology and Diabetes
• Status: Published
• Forskningsgrupp: Genomics, Diabetes and Endocrinology
• ISBN/ISSN/Övrigt: ISSN: 1479-683X